Logo on white.png
EsoCap supports first European EoE Day of the European Society of Eosinophilic Oesophagitis on May 22, 2022
20 mai 2022 05h00 HE | EsoCap AG
Patients with eosinophilic esophagitis (EoE) suffer from severe symptoms including swallowing disorders, food impaction, vomiting, and heartburnEsoCap is currently conducting a randomized,...
Logo on white.png
EsoCap and Upadia sign exclusive licensing agreement combining EsoCap technology with Upadia antibodies for the treatment of Barrett’s esophagus
10 janv. 2022 05h32 HE | EsoCap AG
Licensing deal grants EsoCap exclusive access to Upadia’s monoclonal antibodies for a local therapy for Barrett’s esophagusBarrett’s esophagus, a disease of the esophagus with high unmet medical need,...
Logo on white.png
EsoCap secures new funding
18 nov. 2021 08h30 HE | EsoCap AG
EsoCap successfully closes a private financing round, with investments from existing and new investorsThe new funding was facilitated by EsoCap benefitting from a unique programme implemented by the...